Advanced search
Publication Cover
Renal Failure Volume 35, 2013 - Issue 1
Submit an article Journal homepage
662
Views
8
CrossRef citations to date
0
Altmetric
Clinical Study

Trends and Variations in Intravenous Vitamin D Use among Hemodialysis Patients in the United States

Anne C. BeaubrunDivision of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USACorrespondence[email protected]
,
M. Alan BrookhartDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
,
Betsy SleathDivision of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
,
Lily WangCecil G. Sheps Center for Health Services Research, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
&
Abhijit V. KshirsagarUNC Kidney Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Pages 1-8 | Received 18 May 2012, Accepted 23 Sep 2012, Published online: 22 Oct 2012

REFERENCES

  • Khan S. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci. 2007;333(4):201–207.
  • Dennis VC, Albertson GL. Doxercalciferol treatment of secondary hyperparathyroidism. Ann Pharmacother. 2006;40(11):1955–1965.
  • Martin KJ, González EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis. 2001;38(5):S34–S40.
  • Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;19(5):1174–1181.
  • Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446–456.
  • Tentori F, Albert JM, Young EW, . The survival advantage for hemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2009;24(3):963–972.
  • DOPPS. DOPPS practice monitor. Available at: http://www.dopps.org/DPM/. Accessed May 10, 2012.
  • St. Peter W, Li S, Liu J, Gilbertson D, Arneson T, Collins A. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. Pharmacotherapy. 2009;29(2):154–164.
  •   Massengill D. Tips and tricks III: more unique SAS/GRAPH® maps. SAS Institute. Available at: http://support.sas.com/rnd/papers/sugi30/sasmapping3.pdf. Accessed October 5, 2011.
  • Tentori F, Hunt WC, Stidley CA, . Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70(10):1858–1865.
  • Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(9):1529–1539.
  • Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147(12):840–853.
  • Ginde AA, Liu MC, Camargo CA. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern Med. 2009;169(6):626–632.
  • Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003;25(4):595–602.
  • Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol. 2000;11(2):330–334.
  • Kalantar-Zadeh K, Miller JE, Kovesdy CP, . Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D and survival in hemodialysis patients. J Bone Miner Res. 2010;25(12):2724–2734.
  • U.S. Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
  • St. Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994–2002). Am J Kidney Dis. 2005;46(4):650–660.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.